This is a preprint.
IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHC CII complexes
- PMID: 37873241
- PMCID: PMC10592808
- DOI: 10.1101/2023.10.14.560755
IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHC CII complexes
Update in
-
IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes.Sci Adv. 2024 Jul 12;10(28):eadk2091. doi: 10.1126/sciadv.adk2091. Epub 2024 Jul 12. Sci Adv. 2024. PMID: 38996030 Free PMC article.
Abstract
In diffuse large B-cell lymphoma (DLBCL), the transcription factor IRF8 is the target of a series of potentially oncogenic events, including, chromosomal translocation, focal amplification, and super-enhancer perturbations. IRF8 is also frequently mutant in DLBCL, but how these variants contribute to lymphomagenesis is unknown. We modeled IRF8 mutations in DLBCL and found that they did not meaningfully impact cell fitness. Instead, IRF8 mutants, mapping either to the DNA-binding domain (DBD) or c-terminal tail, displayed diminished transcription activity towards CIITA, a direct IRF8 target. In primary DLBCL, IRF8 mutations were mutually exclusive with mutations in genes involved in antigen presentation. Concordantly, expression of IRF8 mutants in murine B cell lymphomas uniformly suppressed CD4, but not CD8, activation elicited by antigen presentation. Unexpectedly, IRF8 mutation did not modify MHC CII expression on the cell surface, rather it downmodulated CD74 and HLA- DM, intracellular regulators of antigen peptide processing/loading in the MHC CII complex. These changes were functionally relevant as, in comparison to IRF8 WT, mice harboring IRF8 mutant lymphomas displayed a significantly higher tumor burden, in association with a substantial remodeling of the tumor microenvironment (TME), typified by depletion of CD4, CD8, Th1 and NK cells, and increase in T-regs and Tfh cells. Importantly, the clinical and immune phenotypes of IRF8-mutant lymphomas were rescued in vivo by ectopic expression of CD74. Deconvolution of bulk RNAseq data from primary human DLBCL recapitulated part of the immune remodeling detected in mice and pointed to depletion of dendritic cells as another feature of IRF8 mutant TME. We concluded that IRF8 mutations contribute to DLBCL biology by facilitating immune escape.
Similar articles
-
IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHCII complexes.Sci Adv. 2024 Jul 12;10(28):eadk2091. doi: 10.1126/sciadv.adk2091. Epub 2024 Jul 12. Sci Adv. 2024. PMID: 38996030 Free PMC article.
-
Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.Oncotarget. 2017 Jul 25;8(30):49757-49772. doi: 10.18632/oncotarget.17693. Oncotarget. 2017. PMID: 28537908 Free PMC article.
-
IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).Leuk Lymphoma. 2014 Jan;55(1):136-42. doi: 10.3109/10428194.2013.793324. Epub 2013 Jun 12. Leuk Lymphoma. 2014. PMID: 23573829
-
The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.Blood Rev. 2018 May;32(3):249-255. doi: 10.1016/j.blre.2017.12.001. Epub 2017 Dec 20. Blood Rev. 2018. PMID: 29289361 Review.
-
Role of IRF8 in immune cells functions, protection against infections, and susceptibility to inflammatory diseases.Hum Genet. 2020 Jun;139(6-7):707-721. doi: 10.1007/s00439-020-02154-2. Epub 2020 Mar 30. Hum Genet. 2020. PMID: 32232558 Review.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials